Prime Medicine Performs First In Vivo Gene Editing
The company successfully treated a patient by rewriting DNA directly inside the body to address Wilson disease.
Updated on Oct. 22, 2026 in Biotech
Live Poll
Is now a good time to move forward with direct in-body human gene editing treatments?
Prime Medicine has conducted the first human in vivo prime gene editing procedure, marking a milestone in genetic therapy. The clinical trial targets Wilson disease by correcting mutations in the ATP7B gene within liver cells.
Why it matters
This procedure aims to provide a permanent solution for Wilson disease by directly repairing faulty DNA. In vivo editing offers a potential alternative to ex vivo methods by eliminating complex manufacturing steps and speed constraints.
Prime editing functions by rewriting specific DNA segments to correct mutations, in this case within a patient's liver cells. This approach targets the ATP7B gene, which normally encodes a protein responsible for transporting excess copper out of the liver.
The players
Prime Medicine
This biotechnology company is based in Cambridge, Massachusetts, and specializes in developing prime editing therapies.
US Food and Drug Administration
This federal agency is responsible for protecting public health by ensuring the safety and efficacy of medical products including gene therapies.
The details
The treatment targets Wilson disease, a condition caused by ATP7B gene mutations that lead to toxic copper accumulation. By rewriting the DNA within the body, the therapy attempts to restore normal protein function and prevent liver and nerve damage.
Timeline
Prime Medicine treated the first clinical trial participant earlier this month.
Initial results from the study are expected to be announced next year.
The FDA is expected to reach a decision on a separate in vivo CRISPR-Cas9 therapy early next year.
The Tech Race
The emergence of Prime Medicine's in vivo editing follows the regulatory approval of Casgevy, a CRISPR-Cas9 therapy that functions by disabling genes. This development marks an evolution in gene therapy by shifting from simply disabling genes to actively rewriting and correcting them.
While this treatment is currently limited to a clinical trial, the technology could eventually lower the costs and complexity associated with gene therapies compared to existing ex vivo methods. Patients with hereditary conditions may see improved access to corrective treatments if this in vivo approach proves successful.
The takeaway
This medical milestone demonstrates a shift toward more efficient, direct genetic repair that could eventually reshape how hereditary diseases are treated. Future developments will depend on the clinical trial proving that direct DNA rewriting is both safe and long-lasting in human patients.
What happens next
Prime Medicine is scheduled to release the first set of results from its clinical trial in 2027.
Further reading
For more background on the state of gene editing, visit our Biotech section.
Live Poll
Is now a good time to move forward with direct in-body human gene editing treatments?
